Why Advanced Off-Target Analysis Is Critical For CRISPR's Clinical Success

By Morgan Sturgeon, PhD, CRISPR Applications Development Manager

This content is brought to you by Integrated DNA Technologies, a Danaher Operating Company.

CRISPR-Cas genome editing has moved from a breakthrough concept to a clinical reality, redefining how genetic diseases can be treated. As its therapeutic potential expands, so does the need for precision. Even minor off-target edits can carry meaningful safety risks, making robust evaluation essential for clinical success. A comprehensive approach—combining multiple, orthogonal methods—is increasingly viewed as the gold standard for understanding and mitigating these risks. Emerging best practices emphasize not only detection sensitivity, but also reproducibility, regulatory alignment, and biological relevance. Advancing gene editing safely depends on strengthening these frameworks and refining the tools that support them.

Explore how evolving expectations and technologies are shaping the next phase of CRISPR safety assessment.